Compare HXL & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HXL | PCVX |
|---|---|---|
| Founded | 1946 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.1B |
| IPO Year | 1994 | 2020 |
| Metric | HXL | PCVX |
|---|---|---|
| Price | $79.25 | $54.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $81.73 | ★ $98.33 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,893,900,000.00 | N/A |
| Revenue This Year | $10.20 | N/A |
| Revenue Next Year | $12.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $45.28 | $28.09 |
| 52 Week High | $95.22 | $76.61 |
| Indicator | HXL | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 30.30 | 40.80 |
| Support Level | $72.85 | $42.30 |
| Resistance Level | $84.64 | $57.50 |
| Average True Range (ATR) | 2.73 | 3.07 |
| MACD | -1.62 | -0.93 |
| Stochastic Oscillator | 14.09 | 5.10 |
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in the commercial aerospace, defense, and high-performance automotive markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.